Triptorelin injection (Trelstar) is used to treat the symptoms associated with advanced prostate cancer. Triptorelin injection (Triptodur) is used to treat central precocious puberty (CPP; a condition causing children to enter puberty too soon, resulting in faster than normal bone growth and development of sexual characteristics) in children 2 years and older. Triptorelin injection is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the amount of certain hormones in the body.
Triptorelin injection (Trelstar) comes as an extended-release (long-acting) suspension to be injected into the muscle of either buttock by a doctor or nurse in a medical office or clinic. Triptorelin injection (Trelstar) also comes as an extended-release suspension to be injected into the muscle of the buttock or thigh by a doctor or nurse in a medical office or clinic. When used for prostate cancer, an injection of 3.75 mg of triptorelin (Trelstar) is usually given every 4 weeks, an injection of 11.25 mg of triptorelin (Trelstar) is usually given every 12 weeks, or an injection of 22.5 mg of triptorelin (Trelstar) is usually given every 24 weeks. When used in children with central precocious puberty, an injection of 22.5 mg of triptorelin (Triptodur) is usually given every 24 weeks.
Triptorelin may cause an increase in certain hormones in the first few weeks after injection. Your doctor will monitor you carefully for any new or worsening symptoms during this time.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Before receiving triptorelin injection,
Unless your doctor tells you otherwise, continue your normal diet.
Triptorelin injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:
In children receiving triptorelin injection (Triptodur) for central precocious puberty, new or worsening symptoms of sexual development may occur during the first few weeks of treatment. In girls, the onset of menstruation or spotting (light vaginal bleeding) may occur during the first two months of this treatment. If bleeding continues beyond the second month, call your doctor.
Triptorelin injection may cause other side effects. Call your doctor if you have any unusual problems while using this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online ( Web Site ) or by phone (1-800-332-1088).
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at Web Site. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests and take certain body measurements to check your body's response to triptorelin injection. Your blood sugar and glycosylated hemoglobin (HbA1c) should be checked regularly.
Before having any laboratory test, tell your doctor and the laboratory personnel that you are receiving triptorelin injection.
Ask your pharmacist any questions you have about triptorelin injection.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: January 15, 2018.